[Featured Stock] Samsung Je Yak Rises Ahead of Lia Vaccine Phase 3 Clinical Trial Announcement

[Asia Economy Reporter Ji Yeon-jin] On the 10th, Samsung Pharmaceutical is showing strong performance in the Korea Stock Exchange market ahead of the announcement of the Phase 3 clinical trial results for 'Liabex Injection (GV1001)' for pancreatic cancer.

As of 9:34 AM on the same day, Samsung Pharmaceutical was trading at 8,660 KRW, up 1,590 KRW (22.49%) compared to the previous trading day.

Earlier, GemVax & Kael announced on the 7th that the Phase 3 clinical trial results of its affiliate Samsung Pharmaceutical will be presented at the 'American Society of Clinical Oncology (ASCO) 2021' annual meeting on the 4th of next month.

Liabex Injection is a product developed by GemVax using the peptide composition 'GV1001' as a treatment for pancreatic cancer. This clinical trial was conducted from November 2015 to April last year at 16 hospitals nationwide, including Yonsei University Severance Hospital, involving a total of 148 patients with locally advanced and metastatic pancreatic cancer.